Monopar Therapeutics Stock Today
| MNPR Stock | USD 0.66 0 0.30% |
Performance8 of 100
| Odds Of DistressLess than 39
|
Monopar Therapeutics is selling at 0.658 as of the 29th of April 2024; that is -0.3% down since the beginning of the trading day. The stock's lowest day price was 0.63. Monopar Therapeutics has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Monopar Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of March 2024 and ending today, the 29th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of December 2019 | Category Healthcare | Classification Health Care |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 17.45 M outstanding shares of which 150.01 K shares are now shorted by private and institutional investors with about 0.6 trading days to cover. More on Monopar Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 9th of May 2024
Monopar Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Monopar Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Monopar Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Old Name | Minrav Projects Ltd | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Monopar Therapeutics report their recommendations after researching Monopar Therapeutics' financial statements, talking to executives and customers, or listening in on Monopar Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Monopar Therapeutics. The Monopar consensus assessment is calculated by taking the average forecast from all of the analysts covering Monopar Therapeutics. | ||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Monopar Therapeutics' liquidity, profitability, solvency, and operating efficiency, Monopar Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Monopar Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||
Monopar Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Monopar Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Monopar Therapeutics' financial leverage. It provides some insight into what part of Monopar Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Monopar Therapeutics (MNPR) is traded on NASDAQ Exchange in USA. It is located in 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 and employs 9 people. Monopar Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Monopar Therapeutics's market, we take the total number of its shares issued and multiply it by Monopar Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Monopar Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 17.45 M outstanding shares of which 150.01 K shares are now shorted by private and institutional investors with about 0.6 trading days to cover.
Monopar Therapeutics currently holds about 16.46 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Monopar Therapeutics Probability Of Bankruptcy
Ownership AllocationMonopar Therapeutics holds a total of 17.45 Million outstanding shares. Monopar Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Monopar Ownership Details
Monopar Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Monopar Therapeutics jumping above the current price in 90 days from now is about 50.0%. The Monopar Therapeutics probability density function shows the probability of Monopar Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8108. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Monopar Therapeutics will likely underperform. Moreover, monopar Therapeutics has an alpha of 1.8838, implying that it can generate a 1.88 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Monopar Therapeutics to move above the current price in 90 days from now is about 50.0 (This Monopar Therapeutics probability density function shows the probability of Monopar Stock to fall within a particular range of prices over 90 days) .
Monopar Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Monopar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Monopar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Monopar Therapeutics' value.| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2023-12-31 | 37.0 | |
| Fmr Inc | 2023-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2023-12-31 | 0.0 | |
| Two Sigma Securities, Llc | 2023-12-31 | 0.0 | |
| Windsor Advisory Group, Llc | 2023-12-31 | 0.0 | |
| Hrt Financial Llc | 2023-12-31 | 0.0 | |
| Renaissance Technologies Corp | 2023-12-31 | 48.1 K | |
| Vanguard Group Inc | 2023-12-31 | 45.2 K | |
| Geode Capital Management, Llc | 2023-12-31 | 41.2 K | |
| Millennium Management Llc | 2023-12-31 | 29.3 K | |
| Gerber Llc | 2023-12-31 | 28 K |
Monopar Therapeutics Historical Income Statement
Monopar Therapeutics Income Statement is one of the three primary financial statements used for reporting Monopar's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Monopar Therapeutics revenue and expense. Monopar Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Monopar Therapeutics' Total Other Income Expense Net is relatively stable compared to the past year. As of 04/29/2024, Net Interest Income is likely to grow to about 360.8 K, while Selling General Administrative is likely to drop 3,069. View More FundamentalsMonopar Stock Against Markets
Picking the right benchmark for Monopar Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Monopar Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Monopar Therapeutics is critical whether you are bullish or bearish towards Monopar Therapeutics at a given time. Please also check how Monopar Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Monopar Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Monopar Therapeutics Corporate Executives
Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
How to buy Monopar Stock?
Before investing in Monopar Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Monopar Therapeutics. To buy Monopar Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Monopar Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Monopar Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Monopar Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Monopar Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Monopar Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Monopar Stock please use our How to Invest in Monopar Therapeutics guide.
Already Invested in Monopar Therapeutics?
The danger of trading Monopar Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Monopar Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Monopar Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Monopar Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Monopar Therapeutics is a strong investment it is important to analyze Monopar Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monopar Therapeutics' future performance. For an informed investment choice regarding Monopar Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Monopar Stock analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Monopar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Return On Assets (0.54) | Return On Equity (1.07) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.